Innovent Biologics has announced that its drug SINTBILO®, a new anti-PCSK9 monoclonal antibody, will be included in the 2024 National Reimbursement Drug List in China, effective January 1, 2025. This listing marks a significant milestone for the company as it expands into the cardiovascular field, especially with its ability to significantly reduce LDL cholesterol levels, providing an important treatment option for patients suffering from primary hypercholesterolemia and mixed dyslipidemia.
SINTBILO® is expected to offer multiple dosing options of 150mg every two weeks, 450mg every four weeks, and 600mg every six weeks, enabling flexibility for healthcare providers and patients. This innovative treatment can reduce LDL cholesterol by nearly 70% and lipoprotein (a) by nearly 50%, which is crucial for patients' cardiovascular health.
As the first domestic PCSK9 inhibitor listed on the NRDL, SINTBILO® plays a crucial role in improving cholesterol management in China. This will potentially enhance the quality of life for a wide array of patients suffering from hypercholesterolemia.
The inclusion of SINTBILO® in the NRDL represents not only a victory for Innovent Biologics but also a significant advancement in the availability of effective treatments for lipid disorders, reflecting the growing focus on comprehensive healthcare solutions in China.
Collection
[
|
...
]